This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates Results showing the clinical utility of the test have been published in Lancet Oncology and the Journal of National Cancer Institute The MAF Test® is now available to oncologists and pathologists in United Kingdom and Ireland and will benefit an estimated 56,000 new patients each year This agreement follows Inbiomotion’s recent distribution partnerships for Spain and Portugal with Palex Medical a